The immune system is naturally programmed to seek out and destroy abnormal cells. Cancer is believed to thrive because of a number of cellular mechanisms that aid in the evasion of immune response. Immuno-oncology therapies that overcome immune suppression by stimulating responses directed to cancer cells may be a powerful means of counteracting the cellular mechanisms that enable the growth and spread of tumors. Immuno-oncology agents are rapidly emerging as a potential path to durable and long-lasting responses in certain patients.

This approach is now focused on the mobilization of both adaptive and innate immunity, including immuno-oncology (IO) therapeutics, connecting bispecific antibodies, and adoptive T cell and NK cell therapies. By addressing the fundamental biology underlying cancer’s evasion and metastasis, our novel therapeutic candidates are intended to improve patient quality of life and lead to more durable survival.